On 3 July 2026, the Medicines and Healthcare products Regulatory Agency approved semaglutide (Wegovy) for adults with metabolic-associated steatohepatitis, or MASH, who have moderate-to-advanced liver fibrosis. The new indication sits alongside existing authorisations for weight management in adults and adolescents and for reducing cardiovascular events in adults. The immediate effect is regulatory rather than operational. According to the government notice, the MHRA has concluded that the current evidence supports use in this patient group, but the decision does not by itself create routine NHS access.
MASH is a progressive liver disease in which excess fat in the liver leads to inflammation and scarring. The notice says the risk is higher in people with obesity, type 2 diabetes and raised blood lipid levels, placing the approval within the wider policy agenda on obesity, metabolic illness and long-term pressure on liver services. The decision is also notable because it extends a medicine already familiar in obesity care into a new disease area. That matters for commissioners and clinicians, as semaglutide is now moving across multiple care pathways rather than being confined to a single specialty.
The MHRA has granted this use under a conditional marketing authorisation, not a full one. In practical terms, that means the medicine can be authorised for MASH while further confirmatory evidence on efficacy and safety is still being collected. The government notice states that additional results from an ongoing study in adults with MASH and moderate-to-advanced liver scarring must be submitted. The MHRA will review new information at least annually and update the Summary of Product Characteristics if required, so the regulatory position remains subject to active evidence review.
The access question now shifts to the National Institute for Health and Care Excellence. Patients with MASH are not currently able to receive semaglutide for this indication on the NHS, because NICE is still assessing its clinical and cost effectiveness. That distinction is central to understanding the announcement. MHRA authorisation determines whether a medicine may be marketed for a defined use, while NICE appraisal informs whether routine NHS funding should follow. Until that appraisal is complete, this remains a licensing development rather than a service rollout.
The MHRA describes semaglutide as a prescription-only GLP-1 receptor agonist to be used alongside diet and exercise. It works by mimicking a hormone released after eating, which helps patients feel fuller for longer and reduces food cravings. The dosing schedule in the notice starts at 0.25 mg once weekly and rises through 0.5 mg, 1 mg and 1.7 mg at four-week intervals to a maintenance dose of 2.4 mg once weekly. The same notice says that, for patients with obesity and a body mass index above 30, the dose can increase to 7.2 mg once weekly after at least four weeks on 2.4 mg.
Julian Beach, the MHRA's Executive Director of Healthcare Quality and Access, said the available evidence indicates that semaglutide is a safe and effective option for patients with MASH, while stressing that it should be used only in consultation with a doctor. The most common side effects listed in the notice are gastrointestinal, including nausea, diarrhoea, constipation and vomiting. Authorisation for the new indication was granted to Novo Nordisk on 3 July 2026. The Summary of Product Characteristics and patient information leaflet are due to appear on the MHRA products site within seven days of approval. For patients, clinicians and commissioners, the next material step is the NICE decision on whether this licensed treatment becomes routinely available on the NHS.